Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors

NCT04056910 is registered in ClinicalTrials.gov with Jason J. Luke, MD as lead sponsor.

NCT NCT04056910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04056910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors
Lead sponsor
Jason J. Luke, MD
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2021
Completion date
November 13, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, glioma, idh1 mutation